Medpace Holdings, Inc. - Common Stock (MEDP)

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme...

The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta y...

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...

Businesses with strong free cash flow tend to be more adaptable and resilient. Some of these companies shine bright by using their cash wisely to strengthen ...

Shareholders of Medpace would probably like to forget the past six months even happened. The stock dropped 28.2% and now trades at $423.89. This may have inv...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking a...

Medpace’s first quarter was marked by substantial year-over-year revenue growth, but management’s discussion centered on increased project cancellations and ...

Clinical research company Medpace Holdings (NASDAQ:MEDP) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 26.5% year on year to $706.6 mil...

Medpace (MEDP) Q1 2026 Earnings Transcript

Clinical research company Medpace Holdings (NASDAQ:MEDP) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 26.5% year on y...

Medpace (MEDP) Q2 2025 Earnings Transcript

Clinical research company Medpace Holdings (NASDAQ:MEDP) will be reporting earnings this Wednesday after the bell. Here’s what to look for. Medpace beat anal...

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man...

Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three ...

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Cas...

Over the past six months, Medpace’s shares (currently trading at $483.21) have posted a disappointing 11.2% loss while the S&P 500 was down 5.5%. This might ...

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services ind...

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva...

Companies with solid operating margins have a competitive edge, allowing them to reinvest for sustainable expansion. The best of these businesses balance pro...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how drug development inputs & services stocks fared in Q4, starting with Medpace (NASDAQ:MEDP).